equityflowunderstand the flow and follow it

Actithera

Biotech · Oslo, NO

Biotech developing small-molecule radioligand therapies targeting fibroblast activation protein for cancer.

Founders

Andreas Goutopoulos (Greece · ♂) — A medicinal chemist with 25+ years in pharma R&D who led drug discovery at EMD Serono and was an EIR at M Ventures, he founded Actithera in 2021 to turn medicinal-chemistry insights into next-generation radioligand cancer therapies.

Date	Round	Amount
Jul 2025	Series A Actithera closed a $75.5M Series A co-led by M Ventures, Hadean Ventures, Sofinnova Partners and 4BIO Capital to advance its radioligand therapy pipeline into the clinic.	$75.5M

Tap an investor to see what else they have backed.

Data is community-curated and may be incomplete.